Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial

BACKGROUND: Low-dose colchicine reduces cardiovascular events in patients with chronic coronary disease. However, side effects may compromise compliance and lead to discontinuation of treatment. Therefore, we aimed to assess the incidence of side effects leading to discontinuation of treatment in the LoDoCo2 (Low-Dose Colchicine 2) trial. METHODS: The LoDoCo2 trial was a randomized controlled trial evaluating colchicine versus placebo in patients with chronic coronary disease. Participants entered a 30-day open-label run-in phase during which all participants received colchicine 0.5 mg once daily, followed by randomization to colchicine or placebo. Tolerability-related side effects leading to treatment discontinuation were evaluated at the end of the 30-day run-in phase and during the randomized phase (median follow-up, 29.5 [interquartile range, 21.6-47.4] months). Cumulative incidence of side effects was presented using Kaplan-Meier curves and compared by treatment arm using Cox proportional hazards models. RESULTS: During the 30-day run-in phase, 618 of 6519 (9.5%) participants reported side effects. Women had a higher risk of side effects than men during the 30-day run-in phase (odds ratio, 1.53 [95% CI, 1.23-1.89]). After randomization, 114 participants (4.2%) in the colchicine group and 120 (4.4%) in the placebo group discontinued treatment due to side effects (hazard ratio [HR], 0.95 [95% CI, 0.73-1.22]). Gastrointestinal symptoms were most common (colchicine 2.0% versus placebo 1.7%) followed by myalgia (colchicine 1.2% versus placebo 1.6%). No differences in the risk of side effects between colchicine and placebo were seen for any of the subgroups. Women did have a higher risk of reporting side effects compared with men, regardless of assigned treatment (HR, 1.66 [95% CI, 1.22-2.25]). CONCLUSIONS: In patients with chronic coronary disease that tolerated initial treatment with low-dose colchicine, long-term discontinuation due to side effects was uncommon and did not differ between colchicine and placebo. REGISTRATION: URL: https://www.anzctr.org/au; Unique identifier: ACTRN12614000093684.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-12
DOI
https://doi.org/10.1161/jaha.126.049844
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial

Marte F. van der Bijl, Niekbachsh Mohammadnia, Jan Hein Cornel, Aernoud T.L. Fiolet et al.
Journal of the American Heart Association
Antiplatelet Therapy and Cardiovascular Diseases
article

Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial

Marte F. van der Bijl, Niekbachsh Mohammadnia, Jan Hein Cornel, Aernoud T.L. Fiolet, J. Van der Veen, Jeanine E. Roeters van Lennep, Amber van Broekhoven, Arend Mosterd, Astrid Schut, Tjerk S.J. Opstal, Charley Ann Budgeon, Stefan Mark Nidorf, Frank L.J. Visseren, Fabrice M A C Martens, Hester M. den Ruijter, John W. Eikelboom, Eric H. Boersma, Saloua El Messaoudi, Jan G.P. Tijssen, Jalina Jannink
article en

Abstract

BACKGROUND: Low-dose colchicine reduces cardiovascular events in patients with chronic coronary disease. However, side effects may compromise compliance and lead to discontinuation of treatment. Therefore, we aimed to assess the incidence of side effects leading to discontinuation of treatment in the LoDoCo2 (Low-Dose Colchicine 2) trial. METHODS: The LoDoCo2 trial was a randomized controlled trial evaluating colchicine versus placebo in patients with chronic coronary disease. Participants entered a 30-day open-label run-in phase during which all participants received colchicine 0.5 mg once daily, followed by randomization to colchicine or placebo. Tolerability-related side effects leading to treatment discontinuation were evaluated at the end of the 30-day run-in phase and during the randomized phase (median follow-up, 29.5 [interquartile range, 21.6-47.4] months). Cumulative incidence of side effects was presented using Kaplan-Meier curves and compared by treatment arm using Cox proportional hazards models. RESULTS: During the 30-day run-in phase, 618 of 6519 (9.5%) participants reported side effects. Women had a higher risk of side effects than men during the 30-day run-in phase (odds ratio, 1.53 [95% CI, 1.23-1.89]). After randomization, 114 participants (4.2%) in the colchicine group and 120 (4.4%) in the placebo group discontinued treatment due to side effects (hazard ratio [HR], 0.95 [95% CI, 0.73-1.22]). Gastrointestinal symptoms were most common (colchicine 2.0% versus placebo 1.7%) followed by myalgia (colchicine 1.2% versus placebo 1.6%). No differences in the risk of side effects between colchicine and placebo were seen for any of the subgroups. Women did have a higher risk of reporting side effects compared with men, regardless of assigned treatment (HR, 1.66 [95% CI, 1.22-2.25]). CONCLUSIONS: In patients with chronic coronary disease that tolerated initial treatment with low-dose colchicine, long-term discontinuation due to side effects was uncommon and did not differ between colchicine and placebo. REGISTRATION: URL: https://www.anzctr.org/au; Unique identifier: ACTRN12614000093684.

Journal of the American Heart Association
The University of Western Australia (AU), Harry Perkins Institute of Medical Research (AU), Erasmus MC (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Werkgroep Cardiologische centra Nederland (NL), Amsterdam University Medical Centers (NL), Meander Medisch Centrum (NL), GenesisCare (AU), McMaster University (CA)
Good health and well-being
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon